Application value of levocarnitine in elderly patients with diabetic kidney disease on maintenance hemodialysis
CSTR:
Author:
Affiliation:

(Department of Nephrology, Tangdu Hospital of Air Force Medical University, Xi′an 710038, China)

Clc Number:

Fund Project:

This work was supported by the Key Research and Development Program of Shaanxi Province (S2022-YF-YBSF-0330).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective To explore the application value of levocarnitine in elderly patients with diabetic kidney disease (DKD) on maintenance hemodialysis (MHD). Methods A total of 252 elderly DKD patients receiving MHD treatment in our hospital from January 2023 to December 2023 were recruited and then randomly divided into a levocarnitine group (routine treatment + levocarnitine, 126 cases) and a control group (routine treatment, 126 cases). After three months of continuous treatment, the changes in laboratory indicators were compared before and after treatment and between the two groups. The incidence of adverse reactions during treatment were observed and recorded. SPSS statistics 24.0 was used for data analysis, and t test or Chi-square test was used for between-group comparison depending on data type. Results Among 252 patients, three cases in each group were excluded. After three months of treatment, the levels of serum β2-microglobulin (β2-MG), serum creatinine (SCr), blood urea nitrogen (BUN), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), lipoprotein-associated phospholipase A2 (Lp-PLA2), C-reactive protein (CRP) and interleukin-6(IL-6) were significantly reduced in both groups when compared with those before treatment, and these above levels were obviously lower in the levocarnitine group than the control group (P<0.05). Serum albumin (ALB), geriatric nutritional risk index (GNRI) and high-density lipoprotein cholesterol (HDL-C) were significantly risen in the two groups than those before treatment, and these indicators were notably higher in the levocarnitine group than the control group (P<0.05). The levels of fasting blood glucose (FBG), 2h postprandial blood glucose (2hPG) and glycosylated hemoglobin (HbA1c) were significantly declined in both groups after three months of treatment than the levels before treatment (P<0.05), but there were no statistical differences between groups after treatment (P>0.05). No notable difference was observed in the incidence of adverse reactions between the levocarnitine group and the control group (3.25% vs 0.00%, P>0.05). Conclusion Levocarnitine combined with routine symptomatic treatment has high application value in the elderly DKD patients on MHD. It can improve lipid metabolism and nutritional status, and relieve inflammatory response, and may be beneficial to protecting renal function in the patients.

    Reference
    Related
    Cited by
Get Citation
Related Videos

Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:August 12,2024
  • Revised:
  • Adopted:
  • Online: August 25,2025
  • Published:
Article QR Code